AFT Pharmaceuticals' announced it is building momentum in the pivotal North American market with the appointment of Toronto-based Dr Ted Witek to the board and the launch of its Maxigesic pain relief medicine in Canada. Dr Witek, an American professional director, healthcare advisor and academic, joins the board on 1 January 2021 as an independent non-executive director. He strengthens the board's experience with North American pharmaceutical regulators and markets. His appointment is a recognition of the importance AFT attaches to its success in the North American market. Dr Witek brings to AFT more than three decades of international clinical development and leadership experience. He will be replacing independent non-executive director Jim Burns who has indicated his wish to step down from the AFT board at the next annual meeting in August 2021.